ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1545

Serum Periostin: a New Marker Of Local Bone Formation In Early Inflammatory Back Pain: results From The DESIR Cohort

Karine Briot1, Simon Paternotte2, Didier Borderie3, Corinne Miceli-Richard4, Maxime Dougados2 and Christian Roux1, 1Cochin hospital, Paris Descartes University, Paris, France, 2Cochin Hospital, Paris Descartes University, Paris, France, 3Laboratoire de Biochimie, Hopital Cochin, Paris Descartes University, Pris, France, 4Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Bone metabolism and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Periostin is a secreted, homodimeric protein that is synthesized by mesenchymal cells of the periosteum, which is involved in osteoblast homeostasis of the periosteum and could be one of the mediators of local bone formation in response to mechanical stress and/or inflammation. Our hypothesis is that periostin could be involved in the syndesmophyte formation in spondyloarthritis. The objective was to assess the relationships between serum periostin levels, bone formation regulators (sclerostin, Dickkof-1 (DKK-1)) and presence of syndesmophyte, in a cohort of early inflammatory back pain (IBP) suggestive of axial spondyloarthritis.  

Methods: The DESIR cohort is a prospective, multicenter French cohort of patients with early IBP (Calin or Berlin criteria) (>3 months and <3 years of duration) suggestive of axial SpA, including 708 patients. All SpA patients were naive of any TNF blocker at inclusion in the study. Serum periostin levels were assessed at baseline in the whole cohort by sandwich enzyme-linked immunosorbent assay (ELISA) (Nordic Biosite, Sweden). Demographic characteristics, disease activity parameters, bone mineral density measurements were assessed at baseline and 2 years.  DKK-1 and SOST serum levels (by sandwich ELISA), radiographs and MRI of axial skeleton (spine and sacroiliac joints) were performed at baseline. Correlations between serum periostin levels with baseline and 2 year variables were tested. 

Results: Serum periostin was available in 701 patients (mean age 33.7±8.6 years, 46.2% of males). Mean (±SD) serum level of periostin was 396.5±461.4 pg/mL. Levels were higher in men (431.5±486.5 pg/mL) than in women (366.4 ±113.7 pg/mL) and decreased with age. Patients with at least one syndesmophyte at baseline had a lowest level of serum periostin than patients without syndesmophytes (222.4 ±286.5 ng/ml vs 412.89 ±471.3 ng/ml, respectively, p=0.021). There was a significant correlation between serum periostin levels and baseline sclerostin levels (r= -0.09; p=0.02) and baseline DKK-1 levels (r=-0.12; p=0.002). Serum periostin levels were weakly correlated with 2-year changes in disease activity parameters: CRP (p=-0.1; 0.027), ESR (r=-0.14; p=0.002), BASDAI (r=-0.12; p= 0.003) and ASDAS CRP (r=-0.18; p=≤0.0001). We did not find any difference between patients with and without the presence of bone marrow oedema on MRI. Serum periostin was not correlated with low BMD (Z≤-2 at at least one site) and was not a predictor of significant bone loss (decreased in BMD ≥0.03g/cm at at least one site).

Conclusion: This study conducted in a large cohort of patients with early axial SpA shows that low serum level of periostin is associated with local bone formation. Periostin is correlated to serum sclerostin and DKK-1 levels and parameters of inflammation. Relationship between serum periostin and formation of new syndesmophyte will be studied using the 2-year centralized analysis of X-rays and MRI.


Disclosure:

K. Briot,
None;

S. Paternotte,
None;

D. Borderie,
None;

C. Miceli-Richard,
None;

M. Dougados,
None;

C. Roux,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-periostin-a-new-marker-of-local-bone-formation-in-early-inflammatory-back-pain-results-from-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology